Psoriatic Arthritis
News
Brodalumab met primary endpoints, deaths called ‘unrelated’
The interleukin-17 inhibitor brodalumab met its co-primary endpoints in a phase III trial of patients with moderate to severe plaque psoriasis.
Conference Coverage
Expert advises how to use shingles vaccine in rheumatology patients
News
Subclinical inflammation predicts progression from psoriasis to PsA
People with cutaneous psoriasis who have arthralgia and signs of subclinical inflammation on MRI are at an increased risk of progressing to...
Conference Coverage
NNTs show once-unimaginable psoriasis outcomes now readily attainable
Interleukin-17 antagonists achieve PASI-90 response in a majority of psoriasis patients.
Conference Coverage
Registry shows no increased cancer risk with biologics for psoriasis
Updated results from PSOLAR registry.
Conference Coverage
Consider comorbidities in psoriasis treatment for better outcomes
Emerging data increasingly link psoriasis with cardiovascular disease, diabetes, and depression, leading one expert to suggest a more integrated...
Commentary
Biosimilar program reshapes FDA’s objectivity
News
Biosimilar infliximab gains FDA Advisory Committee endorsement
News
SCCA2: Potential biomarker for psoriasis severity and treatment efficacy
Serum squamous cell carcinoma antigen 2 was significantly higher in both skin and serum of patients with psoriasis, compared with healthy...
Conference Coverage
VIDEO: Ken Gordon’s pro tips on using biologics in psoriasis
“Look at the patient in front of you.” That’s the advice from Dr. Kenneth B. Gordon on using biologics in harder-to-treat patients with psoriasis...
News
Step therapy and biologics: An easier road ahead?
Payers’ fail-first policies pose special concerns for clinicians treating with biologic therapies. Until these become cheaper, navigating them...